Efficacy, safety, pharmacokinetics, immunogenicity, and serum neutralizing activity of AZD7442 (tixagevimab-cilgavimab) in patients hospitalized with COVID-19: long-term results from the DisCoVeRy trial.
Clément R Massonnaud, Nathan Peiffer-Smadja, Pascal Poignard, Simon Jamard, François Goehringer, François Danion, Jean Reignier, Nathalie de Castro, Denis Garot, Eva Larranaga Lapique, Karine Lacombe, Violaine Tolsma, Emmanuel Faure, Denis Malvy, Thérèse Staub, Johan Courjon, France Cazenave-Roblot, Anne Ma Dyrhol Riise, Paul Leturnier, Guillaume Martin-Blondel, Claire Roger, Karolina Akinosoglou, Vincent Le Moing, Lionel Piroth, Pierre Sellier, Xavier Lescure, Marius Trøseid, Philippe Clevenbergh, Olav Dalgard, Sébastien Gallien, Marie Gousseff, Paul Loubet, Fanny Vardon-Bounes, Clotilde Visée, Leila Belkhir, Élisabeth Botelho-Nevers, André Cabié, Anastasia Kotanidou, Fanny Lanternier, Elisabeth Rouveix-Nordon, Susana Silva, Guillaume Thiery, Guislaine Carcelain, Alpha Diallo, Noémie Mercier, Vida Terzić, Maude Bouscambert-Duchamp, Alexandre Gaymard, Grégory Destras, Laurence Josset, Drifa Belhadi, Nicolas Billard, Jérémie Guedj, Thi-Hong-Lien Han, Sandrine Couffin-Cadiergues, Aline Dechanet, Christelle Delmas, Hélène Esperou, Claire Fougerou-Leurent, Soizic Le Mestre, Annabelle Métois, Marion Noret, Isabelle Bally, Sebastián Dergan-Dylon, Sarah Tubiana, Ouifiya Kalif, Nathalie Bergaud, Benjamin Leveau, Joe Eustace, Richard Greil, Edit Hajdu, Monika Halanova, Jose-Artur Paiva, Anna Piekarska, Jesus Rodriguez Baño, Kristian Tonby, Milan Trojánek, Sotirios Tsiodras, Serhat Unal, Charles Burdet, Dominique Costagliola, Yazdan Yazdanpanah, France Mentré, Florence Ader, Maya Hites, DisCoVeRy study group
Clin Microbiol Infect 32(4) 618-628
摘要
摘要
OBJECTIVES: To report long-term clinical efficacy, safety, pharmacokinetics, immunogenicity and seroneutralization results of AZD7442 (monoclonal antibodies tixagevimab-cilgavimab) in patients hospitalized with COVID-19. METHODS: In this phase 3, double-blind, randomized, multicentre trial, hospitalized adults with PCR-confirmed SARS-CoV-2 infection were randomly assigned 1:1 to receive AZD7442 or placebo, and followed-up until day 456, with repeated blood sample collections until day 365. Clinical endpoints included clinical status, mortality, rehospitalization, SARS-CoV-2 reinfection, and adverse events. Antidrug antibodies and serum drug concentrations were measured. Analyses were performed on the modified intention-to-treat (mITT) populations, defined as participants who actually received the intervention. RESULTS: Between April 28, 2021, and June 23, 2022, 237 participants were randomly assigned to AZD7442 (n = 127) or placebo (n = 110), and 123 participants actually received AZD7442. Participants were infected with pre-Omicron variants in 58.8% (133/226) of cases, versus 33.2% (75/226) of Omicron BA1, BA2, or BA5, and 8% (18/226) missing data. There was no significant difference in the distribution of the 7-point ordinal scale between the AZD7442 and placebo groups, either on day 15 (primary endpoint) (OR = 0.93 [0.54-1.61], p 0.81), or any other time point. Significantly more rehospitalizations occurred between discharge and day 456 among participants who received AZD7442 in the global mITT population (OR = 2.04 [1.03-4.05], p 0.04), but not in the antigen-positive mITT population (OR = 1.78 [0.80-3.94], p 0.15). No significant differences were observed in mortality, SARS-CoV-2 reinfection, or adverse events. In the AZD7442 group, 12 of 87 participants (13.8%) had treatment-emergent antidrug antibodies versus 5 of 69 (7.2%) in the placebo group (OR = 2.02 [0.66-6.14], p 0.21). Serum drug concentrations were detectable up to day 365 for all sampled participants (35/35). Neutralizing antibody titres were significantly higher in the AZD7442 group up to day 180. CONCLUSIONS: AZD7442 did not demonstrate any clinical benefit and was safe up to 15 months. This study also provides valuable data on the pharmacokinetics, immunogenicity, and neutralizing activity of AZD7442 in patients hospitalized with COVID-19.
KM 提取结果
0 个 Figure · 0 个 KM 面板